Skip to main content
ANAGENICS LIMITED logo

ANAGENICS LIMITED — Investor Relations & Filings

Ticker · AN1 ISIN · AU0000198095 ASX Manufacturing
Open in API
Filings indexed 1,067 across all filing types
Latest filing 2016-04-07 Capital/Financing Update
Country AU Australia
Listing ASX AN1

About ANAGENICS LIMITED

https://anagenics.com

Anagenics Limited is a health and wellness company focused on the development and commercialization of science-based anti-aging and longevity solutions. The company specializes in the research and distribution of clinically validated products targeting hair loss and skin health. Its core portfolio includes the évolis brand, which utilizes proprietary FGF5 inhibitor technology to promote hair growth and improve hair health. Through its subsidiaries, such as Advangen and BLC Cosmetics, the company manages a diverse range of premium skincare and wellness brands. Anagenics operates across international markets, providing consumer-facing products and professional-grade treatments backed by scientific research. The company's strategic focus remains on expanding its presence in the global beauty-tech and wellness sectors by leveraging its intellectual property and distribution networks.

Recent filings

Filing Released Lang Actions
Midkine Strategy Update 2 pages 81.3KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement titled 'MIDKINE STRATEGY UPDATE' from Cellmid Limited. It discusses strategic milestones, corporate structure changes, and clinical development plans related to midkine antibody and protein assets. The content focuses on corporate strategy and operational updates rather than financial results, regulatory filings, or detailed financial statements. It does not contain financial data or earnings information, nor does it announce voting results or management changes. The document is a corporate update announcement about strategy and subsidiary formation, which fits best under Capital/Financing Update (CAP) as it relates to corporate structuring and funding strategy for clinical programs.
2016-04-07 English
Fourth Midkine Symposium to be held in Budapest 2 pages 95.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement about the upcoming 4th Midkine Symposium to be held in Budapest, including details about the event, participants, and the company's research focus. It does not contain financial data, management changes, voting results, or regulatory filings. It is a corporate announcement about a scientific symposium rather than a financial report or regulatory filing. Therefore, it fits best under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2016-04-03 English
Transcript of Cellmid Investor Briefing 2 pages 95.5KB
Call Transcript Classification · 95% confidence The document is titled 'TRANSCRIPT OF CELLMID INVESTOR BRIEFING' and describes a telephone conference held by Cellmid Limited. It includes detailed discussion of company progress, financial figures for H1 FY2016, future plans, and Q&A session content. The text explicitly states it is a transcript of an investor briefing held via telephone conference. There are no indications that this is a formal earnings release or annual/interim report, but rather a full transcript of a conference call. Therefore, the document fits the definition of a Call Transcript (CT). The document length (4509 characters) is consistent with a transcript rather than a brief announcement or report publication notice.
2016-02-28 English
Cellmid to Refinance RnD Loan 2 pages 82.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Cellmid Limited dated 26 February 2016. It details the refinancing of an R&D loan facility, including terms of the loan, interest rates, and share issuance rights related to the loan. The announcement also provides an overview of the company's recent financial performance and business developments, such as revenue increases, product launches, and market expansion plans. There is no detailed financial statement or comprehensive financial report included, nor is this a transcript of a call or a regulatory certification. The document is primarily an update on financing activity and business progress, which fits the category of Capital/Financing Update (CAP). The length of the document (5919 characters) and the content confirm it is a substantive announcement rather than a brief notice or a report publication announcement.
2016-02-25 English
Appendix 4D and Half Year Accounts 25 pages 1.7MB
Regulatory Filings
2016-02-24 English
Cellmid Investor Briefing 2 pages 98.6KB
Investor Presentation Classification · 90% confidence The document is an ASX announcement titled 'CELLMID INVESTOR BRIEFING' dated 23 February 2016. It announces a conference call scheduled for 25 February 2016 to brief the market on operations, sales results, and distribution channels. It mentions that the Appendix 4D and audited Interim Financial Report for the six months ending 31 December 2015 will be available prior to the briefing, but does not contain the actual financial report or detailed financial data itself. The document is primarily an invitation and information about an upcoming investor conference call, including dial-in details and a Q&A session. This fits the definition of a Call Transcript (CT) only if it contained the full transcript, but here it is a briefing announcement and call invitation. It is not a full Interim Report (IR) because it lacks substantive financial data. It is not a Report Publication Announcement (RPA) because it does not announce the publication of a report but rather a briefing event. Given the content, the best fit is Investor Presentation (IP) as it is a detailed presentation for investors focusing on financials, strategy, and market position, albeit in a briefing format. Confidence is high due to clear indicators of an investor briefing and call announcement with operational and sales discussion focus.
2016-02-22 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.